Page last updated: 2024-10-22

dan 2163 and Depression

dan 2163 has been researched along with Depression in 20 studies

Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.

Research Excerpts

ExcerptRelevanceReference
" In a multicentre, 6 months, placebo-controlled trial, amisulpride (50 mg/daily) was compared to imipramine (100 mg/daily) in the treatment of patients with DSM-III-R criteria for primary dysthymia, dysthymia with major depression or major depression in partial remission."9.08Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. ( Boyer, P; Lecrubier, Y; Rein, W; Turjanski, S, 1997)
"The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia."7.71Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002)
" In a multicentre, 6 months, placebo-controlled trial, amisulpride (50 mg/daily) was compared to imipramine (100 mg/daily) in the treatment of patients with DSM-III-R criteria for primary dysthymia, dysthymia with major depression or major depression in partial remission."5.08Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group. ( Boyer, P; Lecrubier, Y; Rein, W; Turjanski, S, 1997)
"Aminosulpiride is a benzamide used to treat acute or chronic schizophrenia Some researchers believe that early improvement of depression symptoms in patients has a certain predictive effect on the recovery of symptoms after drug treatment for schizophrenia."3.96Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study. ( Ni, Y; Pan, A; Wang, G; Zheng, L; Zhou, B, 2020)
"The Brief Psychiatric Rating Scale (BPRS) anxiety/depression subscore has been used to assess affective symptoms in three studies (n = 612) comparing amisulpride (400-800 mg/day, n = 339) with haloperidol (15-20 mg/day, n = 160) and risperidone (8 mg/day, n = 113) in the treatment of acute exacerbations of schizophrenia."3.71Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. ( Möller, HJ; Peuskens, J; Puech, A, 2002)
" SEP-4199 had low rates of individual adverse events (<8%) and minimal effects on weight and lipids; median increases in prolactin were +83."3.11A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. ( Deng, L; Fava, M; Hopkins, SC; Kent, J; Koblan, KS; Loebel, A; Tsai, J, 2022)
"Psychotic depression is classified as a clinical subtype of major depressive disorder."2.73Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression. ( Papadimitriou, GN; Politis, AM; Psarros, C; Soldatos, CR; Theleritis, CG, 2008)
"The pharmacological treatment of fibromyalgia is limited to a few drugs that have been demonstrated to be moderately effective in some but not all dimensions of the disease."2.50Current status of atypical antipsychotics for the treatment of fibromyalgia. ( Calandre, EP; Rico-Villademoros, F; Slim, M, 2014)
"One hundred six consecutive cancer outpatients with depressive symptoms were treated in a prospective, intention to treat, 4-week study, and were evaluated in single-blind with Montgomery Asberg rating scale for depression (MADRS), clinical global impression (CGI) and dosage record treatment emergent symptom scale (DOTES) to assess side effects of treatment."1.34Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies. ( Berra, C; Binaschi, L; Borio, R; Torta, R, 2007)

Research

Studies (20)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's4 (20.00)18.2507
2000's8 (40.00)29.6817
2010's3 (15.00)24.3611
2020's5 (25.00)2.80

Authors

AuthorsStudies
Loebel, A1
Koblan, KS1
Tsai, J1
Deng, L1
Fava, M1
Kent, J1
Hopkins, SC1
Yuan, B1
Yuan, M1
Liu, Y1
Admon, R1
Mellem, MS1
Belleau, EL1
Kaiser, RH1
Clegg, R1
Beltzer, M1
Goer, F1
Vitaliano, G1
Ahammad, P1
Pizzagalli, DA1
Mohamed, AM1
Habib, MZ1
Ebeid, MA1
Abdelraouf, SM1
El Faramawy, Y1
Aboul-Fotouh, S1
Magdy, Y1
Wang, G1
Zhou, B1
Zheng, L1
Ni, Y1
Pan, A1
Smith, RC1
Leucht, S1
Davis, JM1
Pasquini, M1
Berardelli, I1
Calabrò, F1
Roselli, V1
Hefner, S1
Biondi, M1
Rico-Villademoros, F1
Calandre, EP1
Slim, M1
Peuskens, J1
Möller, HJ1
Puech, A1
Kopecek, M1
Bares, M1
Svarc, J1
Dockery, C1
Horácek, J1
Lecrubier, Y3
Quintin, P1
Bouhassira, M1
Perrin, E1
Lancrenon, S1
Carvalho, AF1
Nunes-Neto, PR1
Cavalcante, JL1
Oliveira Lima, MC1
Torta, R1
Berra, C1
Binaschi, L1
Borio, R1
Peritogiannis, V1
Goulia, P1
Pappas, D1
Hyphantis, T1
Mavreas, V1
Politis, AM1
Papadimitriou, GN1
Theleritis, CG1
Psarros, C1
Soldatos, CR1
Boyer, P2
Puech, AJ1
Dewailly, J1
Aubin, F1
Perrault, G1
Schoemaker, H1
Scatton, B1
Turjanski, S2
Rein, W2
Papp, M1
Wieronska, J1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effects of Dopamine on Reward Processing[NCT01253421]Phase 1159 participants (Actual)Interventional2012-02-29Completed
Early Life Stress and Depression: Molecular and Functional Imaging Approaches[NCT01701258]Phase 1153 participants (Actual)Interventional2013-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Effect on Caudate Response to Cues

This statistic shows the effect (beta) that the combination of diagnosis and drug has on caudate activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.2231
MDD-placebo-0.0391
HC-amisulpride-0.0938
HC-placebo0.0582

Effect on Caudate Response to Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on caudate activation after Reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.5783
MDD-placebo-0.2673
HC-amisulpride-0.33
HC-placebo0.1955

Effect on Caudate-dACC Connectivity After Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on functional connectivity between caudate and dorsal anterior cingulate cortex (dACC) in response to reward outcomes (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.3628
MDD-placebo0.3881
HC-amisulpride0.2992
HC-placebo0.6192

Effect on NAcc Response to Cues

This statistic shows the effect (beta) that the combination of diagnosis and drug has on nucleus accumbens (NAcc) activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.2446
MDD-placebo0.0736
HC-amisulpride0.1356
HC-placebo0.2182

Effect on NAcc Response to Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on nucleus accumbens (NAcc) activation after reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.9377
MDD-placebo0.1578
HC-amisulpride0.4018
HC-placebo0.954

Effect on NAcc-MCC Connectivity After Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on functional connectivity between nucleus accumbens (NAcc) and mid-cingulate cortex (MCC) in response to reward outcomes. (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.4375
MDD-placebo0.324
HC-amisulpride0.4846
HC-placebo0.4877

Effect on PST Penalty Learning

This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from penalties during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from penalty trials. (NCT01253421)
Timeframe: administered after scan

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.2428
MDD-placebo0.29
HC-amisulpride0.2207
HC-placebo0.2391

Effect on PST Reward Learning

This statistic shows the effect (beta) that the combination of diagnosis and drug has on the ability to learn from rewards during a Probabilistic Selection Task (PST). A higher effect size indicates greater ability to learn from reward trials. (NCT01253421)
Timeframe: administered after scan

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.6271
MDD-placebo0.7575
HC-amisulpride0.823
HC-placebo0.7545

Effect on Putamen Response to Reward

This statistic shows the effect (beta) that the combination of diagnosis and drug has on putamen activation (beta) after reward outcomes. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: During scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.6338
MDD-placebo0.1709
HC-amisulpride-0.14
HC-placebo0.436

Putamen Response to Cues

This statistic shows the effect (beta) that the combination of diagnosis and drug has on putamen activation after presentation of a cue. Positive values indicate an increase in activation relative to baseline. (NCT01253421)
Timeframe: Scan session

InterventionEffect size (Beta) (Mean)
MDD-amisulpride0.4969
MDD-placebo0.3955
HC-amisulpride0.4169
HC-placebo0.3808

The Effect of Diagnosis on Cortisol Reactivity

"This is a measure of area under the curve in relation to ground, a measure of total cortisol output, in response to acute stress. The acute stressor was the Maastricht Acute Stress Test (MAST). The area under the curve includes all 5 cortisol measures, with one measure before the stressor and the other four measures collected after the stressor. Given that the cortisol data were positively skewed, the cortisol measures were normalized via a log transformation prior to calculating the area under the curve.~Area under the curve with respect to ground (AUCG) is calculated AUC_g=(((cort2_log + cort1_log) * cort_t1_time) / 2)+(((cort3_log+cort2_log)*cort_t2_time)/2)+(((cort4_log+cort3_log)*cort_t3_time)/2)+(((cort5_log+cort4_log)*cort_t4_time)/2). Cort_logs are the log transformed cortisol output data (ng/ml) and the cort_times are the time spans in between each cortisol assessment." (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)

Intervention[log (ng/ml)]*min (Mean)
Control Group156.58
MDD Group186.78
CSA/RES Group152.13
CSA/MDD Group179.16

Cortisol Output in Response to a Stress Manipulation

This statistic shows the impact of the stress manipulation on the participant's salivary cortisol output. Saliva samples were collected at 5 distinct time points throughout the study session. The first saliva sample (Cort 1) was collected when the participant began the eeg session. The second (Cort 2)was taken at the end of the acute stressor. The third (Cort 3) was taken approximately fifteen minutes after the second. The fourth (Cort 4) was taken approximately ten minutes after the third. The fifth (Cort 5) was taken approximately 40 minutes after the fourth. (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)

,,,
Interventionng/ml (Mean)
Cort1Cort2Cort3Cort4Cort5
Control Group9.809.1115.5512.897.07
CSA/MDD Group14.198.6314.3114.2211.01
CSA/RES Group10.159.5110.758.997.41
MDD Group12.5312.2815.2316.3010.34

Dopamine Active Transporter Binding Potential

"Utilizing 11C-altropane during positron emission tomography (PET) scanning allows us to measure dopamine active transporter (DAT) binding potential.~Our outcome measure is Nondisplacable Binding Potential (BPND). BPND refers to the ratio at equilibrium of specifically bound radioligand to that of nondisplaceable radioligand in tissue.~*Higher BPND scores indicate greater binding potential" (NCT01701258)
Timeframe: 1 hour PET scan (Session 3)

,,,
InterventionRatio (Mean)
CaudatePutamenAccumbens
Control Group3.1913.3612.159
CSA/MDD Group3.2163.3182.149
CSA/RES Group3.1753.2412.103
MDD Group3.1613.3592.103

Effects on Major Depressive Disorder and Childhood Sexual Abuse History on Striatal Activity in Response to Neutral and Reward Cues

"This statistic shows the influence of major depressive disorder and childhood sexual abuse history on the strength of striatal activation (caudate, putamen, accumbens) in response to neutral and reward cues during the monetary incentive delay task (MID).~Striatal activation is measured using a statistic called a beta weight. A beta weight is a standardized regression coefficient. Higher beta weights mean greater striatal activation and lower beta weights mean less striatal activation. A negative beta weight would indicate a deactivation." (NCT01701258)
Timeframe: 3 hour Drug & fMRI Session (Session 2)

,,,,,,,
Interventionbeta weight (slope) (Mean)
Caudate Response to Reward CuesCaudate Response to Neutral CuesPutamen Response to Reward CuesPutamen Response to Neutral CuesAccumbens Response to Reward CuesAccumbens Response to Neutral Cues
Control-amisulpride.200.222.608.455.401.016
Control-placebo.468.185.663.518.480.120
CSA/MDD-amisulpride.514.254.550.550.692.385
CSA/MDD-placebo.054-.243.468.357.255.040
CSA/RES-amisulpride.511.050.745.493.679-.123
CSA/RES-placebo.079-.370.419.240.310-.381
MDD-amisulpride.403.047.698.384.351-.111
MDD-placebo.608.156.814.621.428.140

Effects on Major Depressive Disorder and Childhood Sexual Abuse History on Striatal Activity in Response to Neutral and Reward Feedback

"This statistic shows the influence of major depressive disorder and childhood sexual abuse history on the strength of striatal activation (caudate, putamen, accumbens) in response to neutral and reward feedback during the monetary incentive delay task (MID).~Striatal activation is measured using a statistic called a beta weight. A beta weight is a standardized regression coefficient. Higher beta weights mean greater striatal activation and lower beta weights mean less striatal activation. A negative beta weight would indicate a deactivation." (NCT01701258)
Timeframe: 3 hour Session 2 (fMRI session)

,,,,,,,
Interventionbeta weight (slope) (Mean)
Caudate Response to Reward FeedbackCaudate Response to Neutral FeedbackPutamen Response to Reward FeedbackPutamen Response to Neutral FeedbackAccumbens Response to Reward FeedbackAccumbens Response to Neutral Feedback
Control-amisulpride-.613-.793-.533-.375.074-.503
Control-placebo-.273-.105-.131.164.069.109
CSA/MDD-amisulpride-.101-.233-.018-.021-.158.010
CSA/MDD-placebo.040-.608.063-.418.839-.332
CSA/RES-amisulpride-.197-.501-.087-.142-.046-.079
CSA/RES-placebo-.905-.959-.304-.276-.713-.819
MDD-amisulpride-.819-.865-.031-.229-.554-.456
MDD-placebo-.773-.733-.357-.108-.215-.039

The Effect of Major Depressive Disorder and Childhood Abuse History on a Reward-related EEG Component (Reward Positivity Component) While Under Stress

"EEG was recorded during the probabilistic reward task (the PRT task). Participants completed the Probabilistic Reward Task (PRT) twice throughout the experiment, once before stress and once after stress. The stressor was the Maastricht Acute Stress Test (MAST). This statistic shows the effect that childhood sexual abuse (CSA) and diagnosis had on a reward-related positivity EEG component recorded during the PRT, before and after stress.~Higher reward positivity amplitudes indicate a stronger neural response to reward and lower amplitudes indicate a lower neural response to rewards." (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)

,,,
Interventionamplitude (microvolts) (Mean)
Pre MASTPost MAST
Control Group2.712.06
CSA/MDD Group4.153.90
CSA/RES Group2.162.30
MDD Group4.754.99

The Effects of CSA and Diagnosis on PRT Performance Under Acute Stress

The participant's performance on the Probabilistic Reward Task (PRT) was assessed both before and after an acute stressor. The PRT is a behavioral task that measures an individual's ability to learn from rewarding stimuli and incorporate this learning into their response style (response bias). The acute stressor was the Maastricht Acute Stress Test (MAST). The score obtained is a ratio of the number of times participants correctly choose the high reward stimuli versus the low rewarding stimuli. Response bias scores range between -1 and +1. Higher response bias scores indicate a stronger response bias toward high reward stimuli. A negative response bias indicates a stronger bias toward low reward stimuli. (NCT01701258)
Timeframe: 3 hour EEG Session (Session 4)

,,,
InterventionRatio (Response Bias Score) (Mean)
PRT Block1: Before MASTPRT Block2: Before MASTPRT Block1: After MASTPRT Block2: After MAST
Control Group0.0280.1240.1280.245
CSA/MDD Group0.1670.1680.0480.127
CSA/RES Group0.0920.1300.0790.143
MDD Group0.1170.1550.0780.128

Reviews

5 reviews available for dan 2163 and Depression

ArticleYear
Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Psychopharmacology, 2019, Volume: 236, Issue:2

    Topics: Amisulpride; Antidepressive Agents; Antipsychotic Agents; Clozapine; Depression; Humans; Imidazoles;

2019
Is amisulpride safe when prescribed to breast and prostate cancer patients?
    Medical hypotheses, 2013, Volume: 81, Issue:6

    Topics: Amisulpride; Antidepressive Agents; Breast Neoplasms; Depression; Female; Humans; Hyperprolactinemia

2013
Current status of atypical antipsychotics for the treatment of fibromyalgia.
    Drugs of today (Barcelona, Spain : 1998), 2014, Volume: 50, Issue:6

    Topics: Amisulpride; Antipsychotic Agents; Anxiety; Benzodiazepines; Comorbidity; Depression; Dibenzothiazep

2014
[The place of amisulpride in the atypical neuroleptic class].
    L'Encephale, 1996, Volume: 22 Spec No 2

    Topics: Amisulpride; Animals; Depression; Humans; Limbic System; Neurologic Examination; Rats; Receptors, Do

1996
Clinical update on amisulpride in deficit schizophrenia.
    International clinical psychopharmacology, 1997, Volume: 12 Suppl 2

    Topics: Adult; Amisulpride; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Double-Blind

1997

Trials

8 trials available for dan 2163 and Depression

ArticleYear
A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression.
    Journal of affective disorders, 2022, 01-01, Volume: 296

    Topics: Amisulpride; Bipolar Disorder; Depression; Diagnostic and Statistical Manual of Mental Disorders; Do

2022
Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets.
    Computational and mathematical methods in medicine, 2022, Volume: 2022

    Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chlo

2022
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:2

    Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major

2020
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:2

    Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major

2020
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:2

    Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major

2020
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression.
    Biological psychiatry. Cognitive neuroscience and neuroimaging, 2020, Volume: 5, Issue:2

    Topics: Adult; Amisulpride; Antidepressive Agents, Second-Generation; Depression; Depressive Disorder, Major

2020
Hyperprolactinemia after low dose of amisulpride.
    Neuro endocrinology letters, 2004, Volume: 25, Issue:6

    Topics: Adult; Amisulpride; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Depression; Dr

2004
The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
    Acta psychiatrica Scandinavica, 2006, Volume: 114, Issue:5

    Topics: Adult; Affect; Amisulpride; Antipsychotic Agents; Attention; Basal Ganglia Diseases; Benzodiazepines

2006
Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Jul-01, Volume: 32, Issue:5

    Topics: Aged; Aged, 80 and over; Amisulpride; Antidepressive Agents; Antipsychotic Agents; Depression; Drug

2008
Treatment of negative symptoms in schizophrenia with amisulpride.
    The British journal of psychiatry : the journal of mental science, 1995, Volume: 166, Issue:1

    Topics: Adult; Amisulpride; Antipsychotic Agents; Depression; Dose-Response Relationship, Drug; Double-Blind

1995
Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group.
    Journal of affective disorders, 1997, Volume: 43, Issue:2

    Topics: Adult; Aged; Amisulpride; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Depre

1997

Other Studies

7 other studies available for dan 2163 and Depression

ArticleYear
Amisulpride alleviates chronic mild stress-induced cognitive deficits: Role of prefrontal cortex microglia and Wnt/β-catenin pathway.
    European journal of pharmacology, 2020, Oct-15, Volume: 885

    Topics: Amisulpride; Animals; Attention; Behavior, Animal; beta Catenin; Cognition Disorders; Depression; En

2020
Prediction of the significance in the improvement of depression symptoms of amisulpride in the treatment of schizophrenia: an 8-week case-control study.
    Annals of palliative medicine, 2020, Volume: 9, Issue:5

    Topics: Amisulpride; Antipsychotic Agents; Case-Control Studies; Depression; Humans; Psychiatric Status Rati

2020
Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2002, Volume: 12, Issue:4

    Topics: Adult; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Depression; Double-Blind M

2002
Amisulpride augmentation after the failure of citalopram for depression: a case report.
    Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:1

    Topics: Adult; Amisulpride; Citalopram; Depression; Dopamine Antagonists; Drug Therapy, Combination; Female;

2007
Amisulpride in the short-term treatment of depressive and physical symptoms in cancer patients during chemotherapies.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2007, Volume: 15, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Amisulpride; Antipsychotic Agents; Cohort Studies; Depression; Femal

2007
Amenorrhea after sertraline introduction in an amisulpride-treated patient with undiagnosed polycystic ovary disease.
    Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2

    Topics: Adult; Amenorrhea; Amisulpride; Antipsychotic Agents; Depression; Drug Interactions; Female; Humans;

2007
Antidepressant-like activity of amisulpride in two animal models of depression.
    Journal of psychopharmacology (Oxford, England), 2000, Volume: 14, Issue:1

    Topics: Amisulpride; Animals; Antidepressive Agents; Antipsychotic Agents; Depression; Disease Models, Anima

2000